

- **Name:** Inkeun Park
 - **Current Position & Affiliation:** Clinical Associate Professor, Department of Oncology, Asan Medical Center
 - **Country:** Republic of Korea
-

• Educational Background:

- 1998. 3 – 2000. 2: Pre-Medicine, Kyunghee university College of Medicine. Seoul, Korea
- 2000. 3 – 2004. 2: M.D., Kyunghee University College of Medicine, Seoul, Korea
- 2007. 3 – 2009.2: Master of Science, Postgraduate School, University of Ulsan College of Medicine, Seoul, Korea
- 2013.2 - 2017.2: Doctor of Philosophy, Postgraduate School, University of Ulsan College of Medicine, Seoul, Korea
- 2019.9 - 2020.8: Visiting scholarship, Yale School of Medicine, New Haven, CT, US

• Professional Experience:

- 2014.3 – 2015.5: Clinical Assistant Professor, Medical Oncology, Gil Medical Center, University of Gachon College of Medicine, Incheon, Korea
- 2015.6 – 2020.8: Assistant Professor, Medical Oncology, Gil Medical Center, University of Gachon College of Medicine, Incheon, Korea
- 2020.9 – 2022.2: Associate Professor, Medical Oncology, Gil Medical Center, University of Gachon College of Medicine, Incheon, Korea
- 2022.3-Present: Clinical Associate Professor, Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

• Professional Organizations:

- Member, Korean Medical Association
- Member, Korean Association of Internal Medicine
- Member, Korean Society of Medical Oncology
- Member, Korean Cancer Association
- Member, Korean Cancer Study Group
- Special Member, Korean Urological Oncology Society

• Main Scientific Publications:

1. Park JH, Park I, Kim IH, Hur JY, Hwang I, Kim C, Kim HJ, Maeng CH, Park K, Lee MY, Lee HJ, Jung JY, Keam B, Park SH, Lee JL. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. *Curr Probl Cancer*. 2022;46:100848
2. Seo JY, Ahn JY, Keam B, Kim M, Yoon S, Lee JL, Park K, Park I. Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients. *Ann Lab Med*. 2021;41:207-213
3. Park I, Lee JL. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. *Korean J Intern Med* 2020;35:834-853

4. Park I, Kim BS, Lim HY, Kim HJ, Lee HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL: Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU 10-16). *Eur J Cancer* 2020;127:183-190
5. Park JH, Yeo JH, Kim YS, Ahn HK, Sym S, Shin D, Hwang I, Park I, Kim JH. Portal vein stent for symptomatic malignant portal vein stenosis: a single-center experience. *Curr Probl Cancer* 2020;44:100476
6. Lee IH, Kang BW, Kim JG, Bae WK, Ki MS, Park I, Jo JC, Kim JY, Koh SA, Lee KH, Cho YY, Ryoo HM, Kwak SG, Lee JL, Lee SA. Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy. *Korea J Intern Med* 2020;35:185-193
7. Park I, Shim YS, Go H, Hong BS, Lee JL. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures. *BMC Urol* 2019;19:51
8. Park I, Lee HJ, Bae WK, Yoon S, Lee JL: A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component. *Invest New Drugs* 2019;37:1239-1246
9. Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi YJ, Seo JY, Park I, Lee JL: Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: A multicenter retrospective analysis in Korean patients. *Cancer Res Treat* 2019;51:1549-1556